GEN Exclusives

More »

GEN News Highlights

More »
Jul 20, 2007

Abraxis Obtains North American and EU Rights to Biocon’s G-CSF Biosimilar

  • Abraxis BioScience licensed the right to develop a biosimilar version of G-CSF (granulocyte-colony stimulating factor) in North America and the EU from Biocon.

    Therapeutic G-CSF is primarily used for the treatment of neutropenia. Biocon received regulatory approval from the Indian DCGI for the treatment of neutropenia in cancer patients.

    Under the terms of the agreement, Biocon will receive an upfront licensing fee and following approval in the licensed territories, royalties from Abraxis BioScience.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?